Drug Trial Radar · NCT05342636
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jul 27, 2022
Primary completion
Dec 5, 2025
Study completion Dec 5, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with advanced esophageal cancer who have failed 1 prior line of therapy and have not been previously exposed to programmed cell death 1 protein (PD-1)/ programmed cell death ligand 1 (PD-L1) based treatment. With protocol amendment 5 (effective: 17-November-2023), enrollment in study arms "Pembrolizumab plus MK-4830 plus Chemotherapy" and "Pembrolizumab plus MK-4830 plus lenvatinib" is discontinued.
Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
PembrolizumabBiological
200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
Coformulation favezelimab/pembrolizumabBiological
800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
MK-4830Biological
800 mg administered via IV infusion Q3W
LenvatinibDrug
20 mg administered via oral capsules each day
IrinotecanDrug
180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.
PaclitaxelDrug
80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing a Dose-limiting Toxicity (DLT) During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
- Number of Participants Experiencing an Adverse Event (AE) During Safety Lead-in PhaseTime frame: Up to approximately 3 Weeks
- Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
- Objective Response Rate (ORR)Time frame: Up to approximately 40 months
Locations
46 sites in 13 countries. Site status is shown where the registry gives one.
Liga Norte Riograndense Contra o Câncer ( Site 2303)
Natal, Rio Grande do Norte, Brazil
Hospital Nossa Senhora da Conceição ( Site 2301)
Porto Alegre, Rio Grande do Sul, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300)
São Paulo, São Paulo, Brazil
FALP-UIDO ( Site 2400)
Santiago, Region M. de Santiago, Chile
Clínica las Condes ( Site 2403)
Santiago, Region M. de Santiago, Chile
Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104)
Brest, Finistere, France
Hopital Claude Huriez - CHU de Lille ( Site 1100)
Lille, Nord, France
Pitie Salpetriere University Hospital ( Site 1102)
Paris, Orne, France
Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 2804)
Berlin, Germany
Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 2801)
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Duesseldorf ( Site 2802)
Düsseldorf, North Rhine-Westphalia, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 2806)
Dresden, Saxony, Germany
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
Milan, Italy
Istituto Oncologico Veneto IRCCS ( Site 1205)
Padova, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 1206)
Milan, Lombardy, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1200)
Milan, Lombardy, Italy
Aichi Cancer Center Hospital ( Site 1702)
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 1701)
Kashiwa, Chiba, Japan
Saitama Prefectural Cancer Center ( Site 1703)
Ina-machi, Saitama, Japan
Shizuoka Cancer Center ( Site 1704)
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital ( Site 1700)
Chuo-ku, Tokyo, Japan
Oslo universitetssykehus, Radiumhospitalet ( Site 2501)
Oslo, Norway
National University Hospital ( Site 1800)
Singapore, South West, Singapore
Asan Medical Center-Department of Oncology ( Site 1901)
Seoul, South Korea
Samsung Medical Center-Division of Hematology/Oncology ( Site 1900)
Seoul, South Korea
Hôpitaux Universitaires de Genève (HUG) ( Site 2702)
Geneva, Canton of Geneva, Switzerland
Kantonsspital Graubünden-Medizin ( Site 2700)
Chur, Kanton Graubünden, Switzerland
China Medical University Hospital ( Site 2007)
Taichung, Taiwan
Taichung Veterans General Hospital-Radiation Oncology ( Site 2008)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 2001)
Tainan, Taiwan
National Taiwan University Hospital ( Site 2000)
Taipei, Taiwan
Taipei Veterans General Hospital ( Site 2005)
Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 2006)
Taoyuan, Taiwan
Chang Gung Memorial Hospital at Kaohsiung ( Site 2003)
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Chulalongkorn University ( Site 2104)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 2102)
Bangkok, Bangkok, Thailand
Songklanagarind hospital ( Site 2105)
Hat Yai, Changwat Songkhla, Thailand
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1417)
Adana, Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1402)
Ankara, Turkey (Türkiye)
Memorial Ankara Hastanesi-Medical Oncology ( Site 1408)
Ankara, Turkey (Türkiye)
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.